Vanda Pharm (VNDA) Q4 2025 earnings review
Fanapt Surges, But Cash Burn and Tax Charges Cloud the Picture
Vanda delivered a messy Q4. On the surface, the commercial pivot is working: Revenue grew 8% YoY driven by a 25% surge in Fanapt sales. However, the bottom line collapsed with a $141M Net Loss, primarily due to a $113.7M non-cash valuation allowance against deferred tax assets—a signal management doubts near-term profitability. More concerning is the cash burn: cash dropped $111M in FY25 to $264M. While the recent FDA approval of NEREUS and the upcoming Bysanti decision offer promise, the financial runway is tightening.
🐂 Bull Case
The bipolar I launch is a success. Fanapt revenue grew 25% YoY to $33.2M, and New-to-Brand Prescriptions (NBRx) surged 108%. This is no longer a declining franchise; it is an accelerating growth engine.
NEREUS (tradipitant) was approved for motion sickness (first new oral therapy in 40 years). The Bysanti NDA decision is due Feb 21, 2026. This transforms Vanda from a single-product story to a multi-asset commercial pharma.
🐻 Bear Case
Cash and marketable securities fell from $374.6M to $263.8M in FY25. With Operating Expenses up 54% in Q4 to support launches, the runway is shortening just as they need capital for the NEREUS launch.
The $113.7M non-cash charge to write down deferred tax assets is a major red flag. It effectively means management does not expect to generate sufficient taxable income in the near future to utilize these assets.
⚖️ Verdict: ⚪
Neutral. The commercial turnaround of Fanapt is impressive, and the pipeline is delivering approvals. However, the financial cost of this growth—massive cash burn and widening operating losses—makes the stock risky until spending stabilizes.
Key Themes
Fanapt Acceleration
Accelerating. Fanapt has successfully pivoted from a legacy schizophrenia drug to a bipolar I growth asset. Sales grew 25% YoY in Q4 (vs +18% in 24Q4). Total prescriptions rose 36%, and new patient starts more than doubled (+108%). FY26 guidance ($150-170M) implies continued robust growth of ~36% at the midpoint vs FY25.
Cash Position Deterioration
Decelerating. Cash burn has accelerated significantly. The company consumed ~$111M in FY25, ending with $263.8M. Notably, the company ceased providing cash guidance for 2026, limiting guidance only to revenue. This omission suggests uncertainty or lack of visibility regarding spending requirements for upcoming launches (NEREUS, Bysanti).
Valuation Allowance Shock
Vanda recorded a one-time, non-cash tax charge of $113.7M, writing off its deferred tax assets. While non-cash, this is a significant negative signal: accounting rules require this when it is 'more-likely-than-not' that the company will NOT realize these assets (i.e., will not generate sufficient profit) in the foreseeable future.
HETLIOZ Erosion Continues
Decelerating. HETLIOZ continues to bleed revenue due to generic competition, dropping 18% YoY in Q4 to $16.4M. This creates a drag that Fanapt must work harder to offset. The segment is volatile but undeniably shrinking.
PONVORY Slow Ramp
Stable. PONVORY grew 17% YoY to $7.6M, but absolute numbers remain small ($27.4M FY25). It has not yet shown the explosive inflection needed to become a major pillar of the revenue stack alongside Fanapt.
NEREUS Approval
The FDA approved NEREUS (tradipitant) for motion sickness prevention. This is the first new oral therapy for this indication in over 40 years, targeting a population of 65-78 million US adults. Launch preparations are underway, offering a new, potentially large revenue stream starting in 2026.
Other KPIs
Decelerating (worsening). Loss widened significantly from $10.3M in 24Q4. This was driven by a 54% spike in operating expenses to $97.6M, reflecting the heavy cost of the Fanapt commercial push and R&D pipeline.
Stable. Margins remain high. Product revenue was $57.2M with only $3.8M COGS, indicating gross margins above 93%. The issue at Vanda is not unit economics, but SG&A overhead.
Accelerating. Up 60% YoY from $39.3M in 24Q4. This is the primary driver of the cash burn, funding the DTC campaigns and sales force expansion for Fanapt.
Guidance
Accelerating. The midpoint ($245M) implies ~13% YoY growth, an acceleration from the 9% growth seen in FY25. This assumes Fanapt momentum continues and offsets HETLIOZ declines.
Accelerating. Midpoint ($160M) implies ~36% growth over FY25's $117.3M. This confirms management's high confidence in the bipolar indication trajectory.
Reversing. Vanda explicitly limited guidance to revenue, removing the cash guidance provided in previous years. This is a concern given the high burn rate.
Key Questions
Cash Runway and Financing
With cash burn running at ~$110M/year and a balance of $264M, you have roughly 2 years of runway at current spend. Given the planned launches for NEREUS and potentially Bysanti, will you need to raise capital in 2026?
Bysanti Launch Costs
If Bysanti is approved in February, how should we model the incremental SG&A? Will it leverage the existing Fanapt sales force entirely, or will there be significant new launch costs?
HETLIOZ Stability
HETLIOZ is guided implicitly to ~$80-90M (combined with PONVORY). Do you see a floor forming for HETLIOZ in 2026, or should we expect double-digit declines to continue indefinitely?
Tax Charge Clarification
Does the valuation allowance on deferred tax assets imply that you do not expect to be GAAP profitable in FY26 or FY27?